The transcatheter heart valve replacement (THVR) market share in 2026 is expanding as cardiac valve diseases, valve regurgitation, congenital heart conditions, and the demand for minimally invasive treatment options continue to influence healthcare procedures. Transcatheter heart valve replacement provides an alternative approach to traditional surgical valve replacement and includes procedures such as transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), and transcatheter pulmonary valve replacement (TPVR). The increasing adoption of transcatheter technologies, product approvals, reimbursement support, and the introduction of innovative valve systems are contributing to market development.
According to Fortune Business Insights, the global transcatheter heart valve replacement market size was valued at USD 4.04 billion in 2018 and is projected to reach USD 10.34 billion by 2026, exhibiting a CAGR of 12.5% during the forecast period. North America dominated the global market with a 40.1% share in 2018. The region's position was supported by favorable reimbursement policies, product approvals, and the increasing number of transcatheter procedures.
Favorable Health Reimbursement: Government and private reimbursement policies for transcatheter heart valve replacement are supporting procedure volumes and product demand. Fortune Business Insights notes that the U.S. Centers for Medicare & Medicaid Services updated reimbursement policies in June 2019, including procedure-volume requirements for hospitals maintaining transcatheter heart valve replacement programs.
Launch of Innovative Products: The introduction of new transcatheter heart valve products is supporting market growth. The report highlights Medtronic's September 2019 launch of Evolut PRO+, a TAVR system in the U.S., as an example of product development supporting the market.
Growing Need for Minimally Invasive Treatment: Increasing movement toward minimally invasive treatment options is supporting adoption of transcatheter technology. Clinical studies highlighting safety, improved clinical outcomes, and fewer complications compared with surgical valves are also identified as factors supporting demand.
Alternative Surgical Products: The presence of traditional surgical valves remains a restraint, particularly in emerging countries. Surgical valves continue to have demand because of their durability and ability to last for a long period, creating competition for transcatheter valve technologies.
Competition in the THVR market is characterized by product development, approvals, strategic collaborations, and investments in new valve technologies. Manufacturers are increasingly focusing on mitral valve products because of unmet patient needs and the limited availability of products. Several TMVR products were under investigation, creating opportunities for future market development.
Key industry developments include Medtronic's launch of Evolut PRO+ in the U.S., Edwards Lifesciences receiving the CE mark for Edwards SAPIEN 3 for certain patients with aortic stenosis, and Medtronic receiving FDA approval for Melody, a transcatheter pulmonary valve for patients with congenital heart diseases.